Aveanna Healthcare: Q3 Beat And Higher Guidance Back Strong Buy Rating

Aveanna Healthcare (AVAH) reported Q3 earnings beat with 11% revenue growth and 25% adjusted EBITDA increase. Private duty services drove growth, with hours of care up 13 million. The company maintained a Strong Buy rating due to strong growth and profitability.

Original reporting
Published Nov 13, 2026, 6:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 7:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AVAH
Bullish
high confidence
Mentioned
$AVAH
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$AVAHBullishMed
01

Why it matters

The earnings beat and raised outlook reinforce the company's growth narrative.

02

Market read

Earnings beat and guidance raise are likely to drive short‑term buying pressure.

03

What to watch

Potential regulatory or reimbursement changes in the private duty space.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Aveanna Healthcare is a provider of home health and hospice services.

Company-level read

Ticker impact

$AVAHBullishHigh confidence
Context

Aveanna Healthcare reported Q3 earnings beat and raised guidance, supporting a Strong Buy rating.

Expected impact

upward pressure as market prices in the beat and guidance raise

Evidence & confidence

Double earnings beat and guidance lift suggest near‑term buying interest.

Market effects

Strong performance may lift the home health services sector.

U.S. healthcare stocks could see modest gains.

Limited to U.S. markets; no direct global effect.

Counterpoint

If guidance is overly optimistic, the stock could face a pull‑back on follow‑through.

Key entities

  • Aveanna Healthcare Holdings

    Provider of home health services, ticker AVAH.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.

$AVAHHighAI 8/10

Aveanna Healthcare shares fall 6% despite third quarter beat

Aveanna Healthcare (AVAH) reported Q3 earnings of $0.23 per share, beating estimates by $0.02, with revenue of $695.5M, up 11.8% YoY. Despite this, shares fell 6.04% pre-market due to fiscal 2026 guidance that aligned with analyst expectations. The company raised its full-year revenue guidance to over $2.695B and EBITDA guidance to over $374M. All three business segments contributed to revenue growth, and net income rose to $45.5M from $14.1M YoY.